» Articles » PMID: 28542929

The Immune Response to Prevotella Bacteria in Chronic Inflammatory Disease

Overview
Journal Immunology
Date 2017 May 26
PMID 28542929
Citations 591
Authors
Affiliations
Soon will be listed here.
Abstract

The microbiota plays a central role in human health and disease by shaping immune development, immune responses and metabolism, and by protecting from invading pathogens. Technical advances that allow comprehensive characterization of microbial communities by genetic sequencing have sparked the hunt for disease-modulating bacteria. Emerging studies in humans have linked the increased abundance of Prevotella species at mucosal sites to localized and systemic disease, including periodontitis, bacterial vaginosis, rheumatoid arthritis, metabolic disorders and low-grade systemic inflammation. Intriguingly, Prevotella abundance is reduced within the lung microbiota of patients with asthma and chronic obstructive pulmonary disease. Increased Prevotella abundance is associated with augmented T helper type 17 (Th17) -mediated mucosal inflammation, which is in line with the marked capacity of Prevotella in driving Th17 immune responses in vitro. Studies indicate that Prevotella predominantly activate Toll-like receptor 2, leading to production of Th17-polarizing cytokines by antigen-presenting cells, including interleukin-23 (IL-23) and IL-1. Furthermore, Prevotella stimulate epithelial cells to produce IL-8, IL-6 and CCL20, which can promote mucosal Th17 immune responses and neutrophil recruitment. Prevotella-mediated mucosal inflammation leads to systemic dissemination of inflammatory mediators, bacteria and bacterial products, which in turn may affect systemic disease outcomes. Studies in mice support a causal role of Prevotella as colonization experiments promote clinical and inflammatory features of human disease. When compared with strict commensal bacteria, Prevotella exhibit increased inflammatory properties, as demonstrated by augmented release of inflammatory mediators from immune cells and various stromal cells. These findings indicate that some Prevotella strains may be clinically important pathobionts that can participate in human disease by promoting chronic inflammation.

Citing Articles

The Relationship Between Fiber Intake and Gut Bacterial Diversity and Composition During the Third Trimester of Pregnancy.

Schwartz L, Ladouceur J, Russell M, Xie S, Bu S, Kerver J Nutrients. 2025; 17(5).

PMID: 40077643 PMC: 11901921. DOI: 10.3390/nu17050773.


Heart rate variability, daily cortisol indices and their association with psychometric characteristics and gut microbiota composition in an Italian community sample.

Ravenda S, Mancabelli L, Gambetta S, Barbetti M, Turroni F, Carnevali L Sci Rep. 2025; 15(1):8584.

PMID: 40074815 PMC: 11903775. DOI: 10.1038/s41598-025-93137-8.


Combination of gut microbiota, proinflammatory cytokine, and F-FDG PET as potential indicators for predicting breast cancer recurrence.

An J, Kim B, Yoon H Sci Rep. 2025; 15(1):8313.

PMID: 40065046 PMC: 11894217. DOI: 10.1038/s41598-025-92233-z.


Exploring the glucose-lowering and anti-inflammatory immune mechanism of artemether by AMPK/mTOR pathway and microbiome based on multi-omics.

Jiang T, Du P, Liu D, Chen H, Ma Y, Hu B Front Pharmacol. 2025; 16:1520439.

PMID: 40046742 PMC: 11879814. DOI: 10.3389/fphar.2025.1520439.


What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review.

Ferraioli M, Levani J, De Luca R, Matucci-Cerinic C, Gattorno M, Guiducci S J Clin Med. 2025; 14(4).

PMID: 40004896 PMC: 11856149. DOI: 10.3390/jcm14041366.


References
1.
Cekici A, Kantarci A, Hasturk H, Van Dyke T . Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000. 2013; 64(1):57-80. PMC: 4500791. DOI: 10.1111/prd.12002. View

2.
Larsen J, Musavian H, Butt T, Ingvorsen C, Thysen A, Brix S . Chronic obstructive pulmonary disease and asthma-associated Proteobacteria, but not commensal Prevotella spp., promote Toll-like receptor 2-independent lung inflammation and pathology. Immunology. 2014; 144(2):333-42. PMC: 4298427. DOI: 10.1111/imm.12376. View

3.
Morgan X, Tickle T, Sokol H, Gevers D, Devaney K, Ward D . Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012; 13(9):R79. PMC: 3506950. DOI: 10.1186/gb-2012-13-9-r79. View

4.
Nagy E . Anaerobic infections: update on treatment considerations. Drugs. 2010; 70(7):841-58. DOI: 10.2165/11534490-000000000-00000. View

5.
Vazquez-Castellanos J, Serrano-Villar S, Latorre A, Artacho A, Ferrus M, Madrid N . Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol. 2014; 8(4):760-72. DOI: 10.1038/mi.2014.107. View